Barrow Hanley Mewhinney & Strauss LLC Sells 140,540 Shares of Sanofi (NASDAQ:SNY)

Barrow Hanley Mewhinney & Strauss LLC lowered its position in Sanofi (NASDAQ:SNY - Free Report) by 1.8% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 7,697,289 shares of the company's stock after selling 140,540 shares during the quarter. Sanofi comprises approximately 1.3% of Barrow Hanley Mewhinney & Strauss LLC's investment portfolio, making the stock its 29th biggest holding. Barrow Hanley Mewhinney & Strauss LLC owned 0.30% of Sanofi worth $371,240,000 at the end of the most recent quarter.

Several other large investors also recently made changes to their positions in SNY. Vise Technologies Inc. boosted its holdings in shares of Sanofi by 3.0% in the fourth quarter. Vise Technologies Inc. now owns 25,484 shares of the company's stock valued at $1,229,000 after acquiring an additional 754 shares in the last quarter. Focus Partners Advisor Solutions LLC bought a new position in shares of Sanofi in the fourth quarter valued at approximately $502,000. Waverly Advisors LLC boosted its holdings in shares of Sanofi by 71.5% in the fourth quarter. Waverly Advisors LLC now owns 9,790 shares of the company's stock valued at $472,000 after acquiring an additional 4,082 shares in the last quarter. Zimmer Partners LP boosted its holdings in shares of Sanofi by 21.3% in the fourth quarter. Zimmer Partners LP now owns 488,300 shares of the company's stock valued at $23,551,000 after acquiring an additional 85,800 shares in the last quarter. Finally, Vestal Point Capital LP boosted its holdings in shares of Sanofi by 400.0% in the fourth quarter. Vestal Point Capital LP now owns 750,000 shares of the company's stock valued at $36,172,000 after acquiring an additional 600,000 shares in the last quarter. Institutional investors and hedge funds own 14.04% of the company's stock.

Sanofi Stock Up 0.8%

Shares of NASDAQ SNY traded up $0.41 during mid-day trading on Tuesday, reaching $52.39. The company had a trading volume of 1,925,563 shares, compared to its average volume of 2,376,691. Sanofi has a twelve month low of $45.80 and a twelve month high of $60.12. The company has a debt-to-equity ratio of 0.15, a quick ratio of 1.14 and a current ratio of 1.46. The stock has a market capitalization of $132.35 billion, a PE ratio of 21.04, a price-to-earnings-growth ratio of 1.01 and a beta of 0.55. The stock's 50 day moving average is $52.65 and its 200-day moving average is $51.89.

Sanofi (NASDAQ:SNY - Get Free Report) last posted its earnings results on Thursday, April 24th. The company reported $0.94 EPS for the quarter, topping the consensus estimate of $0.90 by $0.04. The firm had revenue of $10.41 billion for the quarter, compared to the consensus estimate of $9.79 billion. Sanofi had a net margin of 12.77% and a return on equity of 25.61%. The business's quarterly revenue was down 11.0% on a year-over-year basis. During the same period in the prior year, the business posted $1.78 earnings per share. As a group, equities analysts anticipate that Sanofi will post 4.36 earnings per share for the current fiscal year.

Sanofi Increases Dividend

The firm also recently announced an annual dividend, which will be paid on Thursday, June 12th. Shareholders of record on Friday, May 9th will be given a dividend of $2.0369 per share. This represents a yield of 3.1%. This is an increase from Sanofi's previous annual dividend of $1.48. The ex-dividend date of this dividend is Friday, May 9th. Sanofi's dividend payout ratio is presently 57.14%.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on SNY. Hsbc Global Res upgraded shares of Sanofi to a "strong-buy" rating in a report on Monday, April 28th. The Goldman Sachs Group began coverage on shares of Sanofi in a report on Friday, March 21st. They set a "neutral" rating and a $65.00 target price for the company. Deutsche Bank Aktiengesellschaft upgraded shares of Sanofi from a "sell" rating to a "hold" rating in a report on Thursday, January 30th. BNP Paribas began coverage on shares of Sanofi in a report on Tuesday, April 15th. They set an "outperform" rating and a $65.00 target price for the company. Finally, Sanford C. Bernstein upgraded shares of Sanofi to a "strong-buy" rating in a report on Thursday, January 30th. Three investment analysts have rated the stock with a hold rating, two have issued a buy rating and three have issued a strong buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Buy" and a consensus target price of $63.33.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.